Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TORNADO: Induction docetaxel + cisplatin + 5-fluorouracil + nivolumab for unresectable locally advanced esophageal cancer
jRCTs031260307Phase 2Recruiting
- Start
- Jul 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab, docetaxel, cisplatin and fluorouracil in Esophageal Squamous Cell Carcinoma (ESCC). Primary endpoint: Progression-free survival. Started Jul 2026; status: recruiting.
02
Drugs
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on jRCTs031260307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031260307.